Replies to post #6405 on Synaptogenix Inc (SNPX)

[Cyosol]

https://www.cnbc.com/2018/07/06/biogen-shares-soar-on-successful-alzheimers-drug-trial.html

"Biogen had a market value of $63 billion as of Thursday’s close."

"Shares of the biotech company were up 15 percent Friday morning, a day after Biogen and Tokyo-based Eisai announced positive results from a Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. The stock move added $9.5 billion in value to Biogen shares."

[runncoach]

Until we get a partner or results of the new trial get close, we may stay under the radar. We got a lot of PR last go around the last 4-6 months before top line results were released. If non-memantine results are confirmed roughly a year from now, there will be no holding this thing back from BP IMO. We just need patience, faith in the drug, and a little bit of good fortune with the science IMO.